欧洲生物技术展览暨会议（BIO-Europe）是欧洲最专业的生物技术及医药、营养品展览会，一年一届，在欧洲各地举行。为期三天的BIO生物技术大会聚集了成千上万名来自多个国家生物技术行业的领袖。大会期间，这些业界领袖将活跃于各类业务拓展活动，机遇层出不穷，合作前景看好。展商在现场能够接触到企业高管以及富有影响力的决策者，这些参观群来到BIO目的就是为了发现生物技术行业内的潜力企业，建立合作伙伴关系，评估新新技术。参加此展将会遇到：成熟和新兴的生物技术公司，制药公司，学术创新，私人投资者包括风险投资和私募股权投资，公司开发的同伴诊断，其他产业相关的服务公司。
BIO-Europe大会吸引了数家机构的若干参会者，这些机构包括顶尖的生物技术企业、制药公司、CRO（合同研发组织）与CMO（合同加工外包组织）20强，以及300多所科研学术机构，如大型研究型实验室、政府机构、咨询服务公司等。并有生物制药领域的专家参会。
欧洲生物技术展商范围：分析服务，生物信息行业，云计算，软件与硬件开发，临床研究报告/临床数据管理，成像软件，信息技术。
展品范围(Show Products):
动植物制药，基因/细胞疗法，生物信息学，基因组学/遗传学，医疗设备，纳米技术，临床研究与实验室服务，平台技术，化学，干细胞研究，给药施药，技术转让，药物研发。
展会报告(Show Reports):
The 30th annual BIO-Europe, the premier partnering conference for the global biopharmaceutical industry, is set to take place November 4–6, 2024, in Stockholm, Sweden.
Partnering is in full swing with meeting requests showing an impressive 61% increase compared to the same point last year, while scheduled meetings have surged by a remarkable 96%. On top of one-to-one meetings, the event will cater to the needs of the entire value chain, with world-class workshops and panels, innovative company presentations, an active exhibition, and a variety of networking opportunities making this event an unrivalled forum for companies to meet and do business.
Celebrating 30 years of pioneering partnerships and life science innovation, this year's BIO-Europe program is inspired by the Swedish approach: an openness to collaboration to advance innovation in the life science industry.
Monday, November 4 will feature "Money Money Money”: Building a robust venture ecosystem for the next generation of innovations. This panel will delve into strategies of how to strengthen the European venture ecosystem in order to support future life science breakthroughs. Industry leaders, including corporate and financial venture capitalists, will discuss strategies to secure funding and ensure a healthy pipeline of innovations. Moderated by Melanie Senior (Nature, evaluate, IN VIVO), panellists will include Laura Lane (Eli Lilly & Co), Mårten Steen (HealthCap), Nick Williams (Medicxi), Lars Gredsted (Lundbeckfonden), and Karl Naegler (Sofinnova Partners).
Tuesday will kick off with "Keep This Fire Burning": Innovate or acquire? Strategic choices for filling pharma pipelines, which will explore the choices large pharmaceutical companies face as they navigate patent expirations and innovation gaps. This panel will discuss varying approaches to fill their pipelines: Do they focus on internal innovation or pursue acquisitions? Featuring experts from leading pharma companies like Chiesi, Novartis, Bayer, Ipsen, and Johnson & Johnson, the session will provide valuable insights into the decision-making processes driving partnerships, M&A, and innovation strategies critical to sustaining long-term industry growth and competitiveness.
The program on Tuesday will continue with “I’ve Been Waiting for You": Rise of novel cardiometabolic therapies, highlighting the transformative developments in therapies targeting cardiometabolic diseases, a major global health challenge. With BioAge Labs’ recent IPO signalling its rising influence, this panel is particularly timely. Discussions will focus on breakthrough innovations in treating age-related and cardiometabolic conditions, featuring insights from key industry players. This session promises to explore cutting-edge research and development that could reshape the future of healthcare and improve patient outcomes worldwide.
